Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Rating of "Buy" by Analysts

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) has been given an average rating of "Buy" by the four research firms that are covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $8.25.

• 6 reasons to buy Teva Pharmaceuticals stock sooner than later

Several analysts have recently commented on AMRX shares. Truist Financial reaffirmed a "buy" rating and issued a $9.00 price objective (up from $7.00) on shares of Amneal Pharmaceuticals in a report on Monday, May 6th. The Goldman Sachs Group upped their price objective on shares of Amneal Pharmaceuticals from $6.25 to $8.00 and gave the company a "buy" rating in a report on Monday, May 6th. StockNews.com downgraded shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Monday, March 4th. Finally, Piper Sandler upped their price objective on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an "overweight" rating in a report on Thursday, March 21st.

Check Out Our Latest Analysis on AMRX

Hedge Funds Weigh In On Amneal Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in Amneal Pharmaceuticals by 0.6% during the first quarter. Vanguard Group Inc. now owns 13,728,233 shares of the company's stock worth $83,193,000 after acquiring an additional 85,846 shares during the period. Rubric Capital Management LP grew its holdings in shares of Amneal Pharmaceuticals by 98.8% during the fourth quarter. Rubric Capital Management LP now owns 8,000,000 shares of the company's stock worth $48,560,000 after buying an additional 3,975,500 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Amneal Pharmaceuticals by 2.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,329,508 shares of the company's stock worth $8,070,000 after buying an additional 26,875 shares in the last quarter. Teacher Retirement System of Texas grew its holdings in shares of Amneal Pharmaceuticals by 3.4% during the fourth quarter. Teacher Retirement System of Texas now owns 744,752 shares of the company's stock worth $4,521,000 after buying an additional 24,651 shares in the last quarter. Finally, Phocas Financial Corp. purchased a new stake in shares of Amneal Pharmaceuticals during the fourth quarter worth $4,339,000. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Stock Up 0.4 %

NASDAQ:AMRX opened at $6.75 on Friday. The company has a market cap of $2.08 billion, a PE ratio of -12.05 and a beta of 1.19. Amneal Pharmaceuticals has a twelve month low of $2.29 and a twelve month high of $7.25. The company has a current ratio of 1.65, a quick ratio of 0.97 and a debt-to-equity ratio of 121.31. The company's 50 day moving average is $6.42 and its two-hundred day moving average is $5.88.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last released its earnings results on Friday, May 3rd. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.04. The company had revenue of $659.19 million for the quarter, compared to the consensus estimate of $623.08 million. Amneal Pharmaceuticals had a negative net margin of 6.76% and a positive return on equity of 234.06%. Analysts anticipate that Amneal Pharmaceuticals will post 0.51 EPS for the current year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.

Featured Articles

• Five stocks we like better than Amneal Pharmaceuticals
• 3 Home Improvement Stocks that Can Upgrade Your Portfolio
• Darden Stock Up After Q4 Earnings Beat, Cautious FY25 Outlook
• 10 Best Airline Stocks to Buy
• Celsius Stock: Why Piper Sandler Forecasts a 50% Surge
• What is the Nikkei 225 index?
• Accenture’s Stock Earnings Reveal an AI-Powered Growth Strategy

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

→ Man Who Called Nvidia at $1.10 Says Buy This Now... (From The Oxford Club) (Ad)

Should you invest $1,000 in Amneal Pharmaceuticals right now?

Before you consider Amneal Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amneal Pharmaceuticals wasn't on the list.

While Amneal Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here